Clin2
NCT06600321Possibly a fitRecruiting

Study of ALN-BCAT for liver cancer

Advanced Hepatocellular CarcinomaMetastatic Hepatocellular Carcinoma

Treatments studied

Part of Cancer, Digestive system clinical trials.

This trial tests a new drug called ALN-BCAT for people with advanced liver cancer (hepatocellular carcinoma) that has a specific genetic change. If you have already tried at least one treatment, this study may be an option for you.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
158 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have been diagnosed with hepatocellular carcinoma, either through a biopsy or, if you have cirrhosis, by standard guidelines.
  • You have already received at least one type of treatment for advanced or spread-out liver cancer.
  • A test shows your tumor has a mutation in the WNT pathway (a specific gene change).
  • Your liver function is stable, meaning it falls into Child-Pugh class A or B7.
  • You have not had other cancer treatments or experimental drugs for at least 3 weeks before starting this study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07227012Recruiting· Phase 1/Phase 2
Study of a new drug for advanced liver cancer

This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.

Irvine, California
NCT06986785Recruiting· Phase 2
Study of new drug combinations for advanced liver cancer

This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.

Shanghai, Shanghai Municipality
NCT07412054Not yet recruiting· Phase 2
Lenvatinib and pembrolizumab with or without BCAA for liver cancer

This trial is testing whether adding a special amino acid supplement (BCAA) to a combination of two drugs (lenvatinib and pembrolizumab) can help treat liver cancer that cannot be removed by surgery. It may be a good option if you have not had similar treatments before and your liver function is still fairly good.

NCT06764316Recruiting· Phase 1
Safety study of BAY 3547926 for advanced liver cancer

This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.

Dothan, Alabama
NCT07317414Recruiting· Phase 2
Beta-alanine for advanced liver cancer

This trial tests whether beta-alanine, a natural supplement, can help people with advanced liver cancer that cannot be removed by surgery. It aims to see if the treatment can slow tumor growth and improve outcomes.

Beijing, Beijing Municipality
NCT07328009Recruiting· Phase 2
Personalized liver cancer treatment trial

This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.

Shanghai, Shanghai Municipality

Hear when a new Advanced Hepatocellular Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.